The phase 1b JAVELIN basket study evaluated the role of avelumab, an anti-PD-L1 targeting agent, for patients after previous treatment with platinum and pemetrexed-based chemotherapy and included 53 patients with mesothelioma, after up to three lines of prior therapy [45]. Here, CD274 is linked to mesothelioma.